Petunina N A, Balabolkin M I, Arion V Ia
Ross Med Zh. 1992(5-12):19-24.
Age-specific and related to DTG severity lowering of T-lymphocyte count, active and autologous T-lymphocyte number, thymic serum activity were found in 83 DTG patients. These shifts made justified the use of immunomodulator tactivin in 32 DTG patients. The drug was administered in daily subcutaneous doses (1 ml of 0.01% solution) for 5 days. As a result, the T-cell immunity returned to normal values. The highest response occurred in young subjects with moderate hyperthyroidism. Because a single tactivin course failed to bring up a persistent effect, repeat courses are needed to achieve good clinical and immunologic responses.
在83例弥漫性毒性甲状腺肿（DTG）患者中发现了特定年龄且与DTG严重程度相关的T淋巴细胞计数降低、活性及自体T淋巴细胞数量减少、胸腺血清活性降低。这些变化使得在32例DTG患者中使用免疫调节剂tactivin具有合理性。该药物以每日皮下注射剂量（0.01%溶液1毫升）给药5天。结果，T细胞免疫恢复到正常水平。最高反应出现在患有中度甲状腺功能亢进的年轻受试者中。由于单一疗程的tactivin未能产生持久效果，需要重复疗程以获得良好的临床和免疫反应。
